PLATELET TRANSFUSIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION - THE PATH PHASE III TRIAL
- Registry ID
- 2068
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- OTTAWA HOSPITAL RESEARCH INSTITUTE
- Start date
- 2021-09-08
- Last update
- 2020-10-29
Conditions
- HEMATOPOIETIC STEM CELL TRANSPLANT
Related clinical trials
- PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE TREATMENT OF PATIENTS WITH VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
- NOVEL PULMONARY FUNCTION MEASURES FOR DIAGNOSIS OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN.
- A RANDOMIZED PILOT TRIAL COMPARING ANTI-THYMOCYTE GLOBULIN (ATG) WITH ATG PLUS POST TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR PROPHYLAXIS AGAINST ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE (GVHD) IN MATCHED DONOR HEMATOPOIETIC CELL TRANSPLANTS (HCT)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE IN SUBJECTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- RANDOMIZED CONTROLLED TRIAL OF OLANZAPINE FOR THE CONTROL OF CHEMOTHERAPY-INDUCED VOMITING IN CHILDREN RECEIVING CHEMOTHERAPY FOR HEMATOPOIETIC STEM CELL TRANSPLANT CONDITIONING
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE 3 STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF CMX001 FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTION IN CMV-SEROPOSITIVE (R+) HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
View on source registry